News & Events

Three-Month Data from the Moderato-HTN Trial Published

December 23, 2017

American Heart Association Journal

3-months data from Moderato-HTN first-in-human clinical study was published in the American Heart Association Journal. The study was an open-label, single-arm, multicenter, prospective trial investigating the safety and efficacy of BackBeat PHC pacing therapy in patients with persistent hypertension indicated for implantation or replacement of a dual-chamber pacemaker.


Abstract on BackBeat® CNT Awarded Best Abstract at the International Conference for Innovations

December 5, 2017

International Conference for Innovation (ICI), Tel Aviv, Israel

BackBeat’s abstract entitled “Two-Year Experience with Programmable Hypertension Control Therapy: A Novel Treatment for Hypertension” was awarded best abstract at the International Conference for Innovation (ICI) that took place in Tel Aviv, Israel on December 3-5, 2017 and helped create a lot of buzz throughout the conference about this transformational therapy.


Angiographic Results and 1-Year Clinical Outcomes from the SABRE Trial Published

October 23, 2017

JACC: Cardiovascular Interventions

Angiographic results and 1-year clinical outcomes of the SABRE (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis) trial were published in JACC: Cardiovascular Interventions, October 2017.


BackBeat Medical Wins Top Honor in TCT 2016 Shark Tank Innovation Competition

November 4, 2016

Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC.

NEW HOPE, Pa., Nov. 4, 2016 /PRNewswire/ -- BackBeat Medical Inc. today announced that the company's patented Programmable Hypertension Control (PHC) therapy received first place in the Shark Tank Innovation Competition at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 conference in Washington, DC.


Results of Multicenter Clinical Study Demonstrate BackBeat's Patented Technology Creates a Potential Breakthrough in Device-Based Treatment of Hypertension

August 28, 2016

The Journal of Innovation in Cardiac Rhythm Management

BackBeat Medical Inc. today announced the presentation of data demonstrating a significant and sustained reduction in blood pressure in patients with hypertension using the company's patented cardiac pacing-based treatment.


Have any questions?
Contact us at 917.254.4900 or info@orchestrabiomed.com